Trial intelligence / Profile preview

Sorafenib with Gemcitabine and Cisplatin in Advanced Biliary Tract Carcinomas

NCT00919061Phase 2Completed

Sponsor
Memorial Sloan Kettering Cancer Center
Start
Aug 2009
Primary completion
Mar 2014
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of sorafenib in biliary tract carcinoma (BTC), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2009; status: completed.

02

Drugs

sorafenib
03

Conditions

biliary tract carcinoma (BTC)

Beyond the preview

Go deeper on NCT00919061.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00919061.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call